Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Preclinical Efficacy of a Novel CD8-Targeted Fusosome for In Vivo CAR T Cell Therapy

Vandana Chaturvedi, Jesse Green, Garrett Zipp, Aaron Lampano, Ouwen Liang, Allison O'Rourke, Brian Granger, Kutlu G Elpek, Neal van Hoeven, Terry Fry

Blood (2023) 142 (Supplement 1): 7121.

https://doi.org/10.1182/blood-2023-189669

Published: 2023

Journal Articles

Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma Patients

Jeremy Kinder, Chanel Athena Estrada, Brian Granger, Allison O'Rourke, Ouwen Liang, Aaron Lampano, Garrett Zipp, Vandana Chaturvedi, Xiaomeng Hu, Chi Young, Neal van Hoeven, Sonja Schrepfer, Terry J. Fry

Blood (2023) 142 (Supplement 1): 3290.

https://doi.org/10.1182/blood-2023-189665

Published: 2023

Journal Articles

In Vitro and In Vivo Specificity and Biodistribution of a Novel CD8-Targeted Fusosome

Hemantkumar Chavan, Shirisha Amatya, Valeria Berlfein, Patricia Cruite, Vandana Chaturvedi, Vasily Vagin, Neal van Hoeven, Jagesh Shah, Terry J. Fry, Boris Gorovits, Sundeep Chandra

Blood (2023) 142 (Supplement 1): 3630.

https://doi.org/10.1182/blood-2023-190158

Published: 2023

Journal Articles

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

Jeremy M. Kinder, Chanel Athena-Estrada, Danyal Malik, Xiaomeng Hu, Meghan Lamba, Chi Young, Neal Van Hoeven, Brian Granger, Vandana Chaturvedi, Ouwen Liang, Jesus Moreno, Aaron Lampano, Garrett Zipp, Adam Johnson, Terry Fry, Sonja Schrepfer, Aaron Foster

Blood (2022) 140 (Supplement 1): 7120–7121.

https://doi.org/10.1182/blood-2022-166845

Published: 2022

Journal Articles

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Vandana Chaturvedi, Nora Lakes, Minh Tran, Natalie Castillo, Michael B. Jordan

Blood (2021) 138 (12): 1034–1039.

https://doi.org/10.1182/blood.2020007930

Published: 2021

Journal Articles

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Vandana Chaturvedi, Rebecca A. Marsh, Adi Zoref-Lorenz, Erika Owsley, Vijaya Chaturvedi, Trung C. Nguyen, Jordana R. Goldman, Michael M. Henry, Jay N. Greenberg, Stephan Ladisch, Michelle L. Hermiston, Michael Jeng, Ahmed Naqvi, Carl E. Allen, Hector R. Wong, Michael B. Jordan

Blood (2021) 137 (17): 2337–2346.

https://doi.org/10.1182/blood.2020009499

Published: 2021

Includes: Supplemental data

Journal Articles

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

David C Fajgenbaum, MDMBA,MSc, Dustin Shilling, PhD, Helen L Partridge, BS, Sheila K Pierson, MS, Jason R Ruth, PhD, Christopher Sheild Nabel, MD PhD, Katie Stone, BS, Vandana Chaturvedi, PhD, Michael B. Jordan, MD, Adam D. Cohen, MD, Vera Krymskaya, PhD, Arthur H Rubenstein, MBBCh, Frits van Rhee, MD PhD, Thomas S Uldrick, MDMS

Blood (2017) 130 (Supplement 1): 3593.

https://doi.org/10.1182/blood.V130.Suppl_1.3593.3593

Published: 2017

NARROW

Preclinical Efficacy of a Novel CD8-Targeted Fusosome for In Vivo CAR T Cell Therapy

Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma Patients

In Vitro and In Vivo Specificity and Biodistribution of a Novel CD8-Targeted Fusosome

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

Email alerts

ASH Publications

American Society of Hematology

Preclinical Efficacy of a Novel CD8-Targeted Fusosome for In Vivo CAR T Cell Therapy

Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma Patients

In Vitro and In Vivo Specificity and Biodistribution of a Novel CD8-Targeted Fusosome

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only